Kai Guo , Xiaoran Feng , Lei Xu , Zhongli Du , Yating Ma , Hong Lu , Chenbin Li , Mingting Peng
{"title":"Unveiling the biological variation of lymphocyte subset counts: Insights from a full-spectrum flow cytometer and the BD MultitestTM 6-Color TBNK kit","authors":"Kai Guo , Xiaoran Feng , Lei Xu , Zhongli Du , Yating Ma , Hong Lu , Chenbin Li , Mingting Peng","doi":"10.1016/j.cca.2025.120152","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and aims</h3><div>To estimate the biological variation (BV) for lymphocyte subset counts in healthy adults based on full-spectrum flow cytometry (FS-FCM) and the most commonly used BD Multitest<sup>TM</sup> 6-Color TBNK kit in China.</div></div><div><h3>Materials and methods</h3><div>The study was designed according to the BV Data Critical Appraisal Checklist (BIVAC). Peripheral blood samples were collected from 60 healthy adults every two weeks for a period of 20 weeks (10 samples from each subject). Lymphocyte subsets were quantified using FS-FCM and the kit mentioned above. Bayesian models were used to analyze within-subject BV (CV<sub>I</sub>) and between-subject BV (CV<sub>G</sub>). Accordingly, the analytical performance specifications (APS) and more were derived. Additionally, the allowable total error (TEa) derived from the BV data in this study was compared with that based on state-of-the-art (SOTA).</div></div><div><h3>Results</h3><div>The CV<sub>I</sub>s for the percentages of CD3<sup>+</sup>, CD3<sup>+</sup>CD4<sup>+</sup>, CD3<sup>+</sup>CD8<sup>+</sup>, CD3<sup>-</sup>CD19<sup>+</sup>, and CD3<sup>-</sup>CD16/CD56<sup>+</sup> cells were 3.60 %, 7.05 %, 4.19 %, 10.73 %, and 19.17 %, respectively. The CV<sub>I</sub>s for the absolute counts were 13.99 %, 13.51 %, 16.19 %, 16.30 %, and 28.64 %, respectively. The CV<sub>G</sub>s for the percentages were 11.78 %, 21.33 %, 35.20 %, 33.69 %, and 44.36 %, and those for the absolute counts were 30.27 %, 28.84 %, 43.11 %, 46.69 %, and 49.21 %, respectively. No significant differences were observed in the CV<sub>I</sub> and CV<sub>G</sub> of males and females. The maximum allowable imprecision parameter based on the BV model was absolute CD3<sup>-</sup>CD16/56<sup>+</sup> cell counts (14.3 %). For most lymphocyte subset parameters, TEa based on SOTA in China was less than the optimal TEa obtained from the BV data of this study.</div></div><div><h3>Conclusions</h3><div>To the best of our knowledge, this study is the first to estimate the BV of lymphocyte subset counts based on FS-FCM and the clinically commonly used BD Multitest<sup>TM</sup> 6-Color TBNK kit.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"569 ","pages":"Article 120152"},"PeriodicalIF":3.2000,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125000312","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and aims
To estimate the biological variation (BV) for lymphocyte subset counts in healthy adults based on full-spectrum flow cytometry (FS-FCM) and the most commonly used BD MultitestTM 6-Color TBNK kit in China.
Materials and methods
The study was designed according to the BV Data Critical Appraisal Checklist (BIVAC). Peripheral blood samples were collected from 60 healthy adults every two weeks for a period of 20 weeks (10 samples from each subject). Lymphocyte subsets were quantified using FS-FCM and the kit mentioned above. Bayesian models were used to analyze within-subject BV (CVI) and between-subject BV (CVG). Accordingly, the analytical performance specifications (APS) and more were derived. Additionally, the allowable total error (TEa) derived from the BV data in this study was compared with that based on state-of-the-art (SOTA).
Results
The CVIs for the percentages of CD3+, CD3+CD4+, CD3+CD8+, CD3-CD19+, and CD3-CD16/CD56+ cells were 3.60 %, 7.05 %, 4.19 %, 10.73 %, and 19.17 %, respectively. The CVIs for the absolute counts were 13.99 %, 13.51 %, 16.19 %, 16.30 %, and 28.64 %, respectively. The CVGs for the percentages were 11.78 %, 21.33 %, 35.20 %, 33.69 %, and 44.36 %, and those for the absolute counts were 30.27 %, 28.84 %, 43.11 %, 46.69 %, and 49.21 %, respectively. No significant differences were observed in the CVI and CVG of males and females. The maximum allowable imprecision parameter based on the BV model was absolute CD3-CD16/56+ cell counts (14.3 %). For most lymphocyte subset parameters, TEa based on SOTA in China was less than the optimal TEa obtained from the BV data of this study.
Conclusions
To the best of our knowledge, this study is the first to estimate the BV of lymphocyte subset counts based on FS-FCM and the clinically commonly used BD MultitestTM 6-Color TBNK kit.
期刊介绍:
The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells.
The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.